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Abstract 43 
Context: Despite the significant risk of regrowth of clinically non-functioning pituitary adenomas 44 
(CNFAs) after primary treatment, systematic data on the probability of further tumor progression and the 45 
effectiveness of management approaches are lacking.  46 
Objective: To assess the probability of further regrowth(s), predictive factors and outcomes of 47 
management approaches in patients with CNFA who have been diagnosed with adenoma regrowth after 48 
primary treatment. 49 
Patients, Design,Setting: Retrospective cohort study on 237 patients with regrown CNFA managed in two 50 
UK referral centers. 51 
Results: Median follow-up was 5.9 years (range 0.4-37.7). The 5-year 2nd regrowth rate was 35.3% (n=90 52 
patients) (36.2% after surgery;12.5% after radiotherapy;12.7% after surgery combined with 53 
radiotherapy;63.4% with monitoring). Of those managed by monitoring, 34.8% eventually were offered 54 
intervention. Type of management and sex were risk factors for 2nd CNFA regrowth. Amongst those with 55 
2nd adenoma regrowth, the 5-year 3rd regrowth rate was 26.4% (24.4% after surgery;0.0% after 56 
radiotherapy;0.0% after surgery combined with radiotherapy;48.3% with monitoring). Overall, patients 57 
with a CNFA regrowth had probability of a 3rd regrowth 4.4% at 5 years, and 10.0% at 10 years, and the 58 
type of management of the 1st regrowth was the only risk factor. Malignant transformation was diagnosed 59 
in two of 237 patients. 60 
Conclusions: Patients with regrown CNFA after primary treatment continue to carry considerable risk of 61 
tumor progression necessitating long-term follow-up. Management approach of the regrowth is the major 62 
factor determining this risk; monitoring has >60% risk of progression at 5 years and a substantial number 63 
of patients will ultimately require intervention.  64 
 65 
 66 
 67 
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Essential points: 68 
 In this retrospective cohort study, we found that clinically non-functioning pituitary adenomas 69 
diagnosed with regrowth after primary treatment continue to carry a considerable risk of further 70 
progression.  71 
 Management approach of the regrowth is the major factor determining the risk of further growth. 72 
 73 
 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
 84 
 85 
 86 
 87 
 88 
 89 
 90 
 91 
 92 
5 
 
Introduction  93 
Clinically non-functioning pituitary adenomas (CNFAs) are pituitary tumors not associated with clinical 94 
evidence of hormonal hypersecretion. They have a prevalence of 7-41.34/100000 people (1-4) and a 95 
standardized incidence rate of 1.02-2.34/100000 (3-5).  96 
Unless incidentally detected, CNFAs usually escape early diagnosis due to the lack of clinical 97 
manifestations of hormonal hypersecretion, and are mostly discovered when they are large enough to 98 
exert pressure effects to surrounding structures. Epidemiological studies suggest that at the time of 99 
detection, 67-90% are macroadenomas representing the clinically relevant tumors in the group of CNFAs 100 
(1,2,5). Surgery with or without adjuvant radiotherapy is the mainstay of treatment for the 101 
macroadenomas, particularly if they are associated with visual compromise or are in close proximity to 102 
the optic pathways. The treatment aims to improve/reverse the consequences of the pressure effects and to 103 
prevent further tumor growth. Despite advances in the surgical and radiotherapy techniques, tumor 104 
control is not always achieved; thus, data from our centres, as well as from other departments, suggest 5-105 
year regrowth rates 15-66% after surgery alone (6-9), and 2-28% after surgery followed by adjuvant 106 
radiotherapy (6,7,10,11). These observations dictate close monitoring, usually with annual imaging in the 107 
early post-operative years, aiming to avoid the consequences of late diagnosis of regrowth.  108 
Management options for regrown CNFAs include further surgery, radiotherapy, a combination of these, 109 
or close monitoring: the decision is influenced by factors including adenoma size/location, patient’s age, 110 
co-morbidities, pituitary reserve, and available surgical and radiotherapy expertise. Despite the significant 111 
risk of CNFA regrowth after primary treatment, series systematically analyzing the outcome of regrown 112 
CNFAs in terms of further tumor progression are lacking. As a result of this, we have no reliable data on 113 
the risk of further regrowth(s) and on the effectiveness of various approaches, and current decisions on 114 
the optimal management of this group of patients lack an evidence base.  115 
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In an attempt to provide this important information, we have performed a collaborative retrospective 116 
cohort study of two large specialist UK referral centers, allowing us to systematically assess the 117 
probability of further CNFA growth, predictive factors and the outcomes of management approaches in a 118 
large series of patients diagnosed with CNFA regrowth and followed-up for a prolonged period. 119 
Furthermore, we have estimated the probability of multiple episodes of adenoma progression after the 120 
first regrowth, providing novel data on the poorly explored area of clinically aggressive CNFA behavior 121 
and resistance to treatments. 122 
 123 
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 125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
 135 
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Patients and Methods 136 
Study design and patients 137 
This was a retrospective cohort study in two large UK specialist referral centers (Birmingham and 138 
Oxford). The records of the patients with histologically-confirmed CNFA who, during their follow-up 139 
were diagnosed with regrowth of the adenoma after primary treatment (this was surgery with or without 140 
adjuvant radiotherapy), were reviewed. These were identified from the databases of the centers in which 141 
patients are classified according to diagnosis. The period covered for the primary surgery of the CNFA 142 
was between January 1963 and December 2011 and the follow-up period ended in June 2016. The term 143 
“primary CNFA” was used to describe the CNFA at the time of original diagnosis (before any regrowth). 144 
The study was retrospective in nature and involved no intervention beyond routine patient care. It was 145 
registered with and approved as an audit by the respective Hospitals. 146 
Adenoma regrowth was diagnosed on the basis of radiological appearances with or without associated 147 
clinical manifestations. The extent of adenoma resection was determined by imaging performed at least 3 148 
months post-operatively. In our series of 237 regrown CNFAs, 94% had tumor residual visible on scan 149 
postoperatively and 6% did not. Subsequent management was based on the decision of the endocrine, 150 
neurosurgical and oncology teams. Imaging surveillance after the detection of regrowth was mostly 151 
performed every 1-2 years. The endpoints were further CNFA regrowths (enlargement after treatment or 152 
further enlargement in cases managed by monitoring).  Follow-up period was defined from the time of 153 
detection of a regrowth until last imaging. Demographic characteristics, treatments, immunohistochemical 154 
and imaging findings, further tumor progression(s), their management and subsequent outcomes were 155 
recorded. 156 
Statistical analyses 157 
Percentages were calculated for categorical data and medians with ranges for continuous variables. The 158 
regrowth-free curves were generated by the Kaplan-Meier method. Cox regression analysis was used to 159 
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assess the effect of various factors on regrowth and Hazard Ratios (HR) with 95% confidence intervals 160 
(CI) were estimated. The number of subjects with no tumor visible on imaging after surgery was very 161 
small and this precluded any analysis based on whether there was visible tumor or not.  There was no 162 
significant departure from proportional hazards assumptions for any of the variables. The level of 163 
significance was set at p<0.05. Statistical analyses were performed by IBM SPSS Statistics for Windows, 164 
Version 22.0. Armonk, NY: IBM Corp. 165 
 166 
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 178 
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Results 181 
Second regrowth 182 
We identified 237 patients with CNFA showing 1st regrowth after primary treatment, representing an 183 
overall 31% of the total of 765 who were treated (9,10,12). Of the 765 patients treated, 678 (88.6%) had 184 
some tumor visible after surgery and 32.9% of these had regrowth, whereas 87 (11.4%) had no tumor 185 
visible after surgery and 16.3% of these had regrowth. In 678 patients with residual tumor, the regrowth 186 
rates were 28.3% without adjuvant irradiation and 4.4 % with adjuvant irradiation. The characteristics of 187 
the 237 patients are shown in Table 1. Eight were diagnosed between 1977 and 1988, and the remaining 188 
ones after 1990.  189 
During a median follow-up of 5.9 years (range 0.4-37.7), 90 patients showed a 2nd regrowth (median age 190 
64.9 years, range 32.3-88.9 – males/females 42/48). The 5-year rate for 2nd CNFA regrowth was 35.3% 191 
(Table 2, Figure 1A). When analyzed based on the type of management for the 1st regrowth, this was 192 
36.2% after 2nd surgery alone (n=33), 12.5% after radiotherapy alone (n=58), 12.7% after 2nd surgery 193 
combined with radiotherapy (n=50), and 63.4% with simple monitoring (n=95) (Table 2, Figure 1B). Of 194 
the CNFAs managed by monitoring after the 1st episode of tumor progression, 34.8% eventually were 195 
offered intervention (surgery or radiotherapy or combination of these) due to further enlargement. 196 
On univariate Cox regression analysis, risk factors for a 2nd regrowth were type of management offered 197 
for the 1st regrowth (type of treatment with reference category “Monitoring”: HR surgery 0.393, 95% CI 198 
0.205-0.754, p=0.005; HR radiotherapy 0.098, 95% CI 0.046-0.210, p<0.001; HR surgery and 199 
radiotherapy 0.174, 95% CI 0.092-0.330, p<0.001), sex (with reference category “Female”: HR in males 200 
0.642; 95% CI 0.423-0.974, p=0.037), and age at diagnosis of the primary CNFA (HR 1.021, 95% CI 201 
1.005-1.038, p=0.009), whereas type of adenoma immunostaining was not (HR 0.833, 95% CI 0.675-202 
1.027, p=0.088). Multivariate regression using the factors significant on univariate analysis revealed that 203 
only the type of treatment and sex (risk lower in males) remained significant risk factors for a 2nd 204 
10 
 
regrowth (type of treatment with reference category “Monitoring”: HR surgery 0.463, 95% CI 0.238-205 
0.901, p=0.023; HR radiotherapy 0.098, 95% CI 0.045-0.212, p<0.001; HR surgery and radiotherapy 206 
0.182, 95% CI 0.093-0.353, p<0.001 - sex with reference category “Female”: HR in males 0.565; 95% CI 207 
0.370-0.863, p<0.008). 208 
 209 
In one of the patients with a 2nd regrowth, the CNFA progression was manifested with metastatic disease 210 
in the brain and spine (pituitary carcinoma with positive staining for gonadotrophins); this was detected 211 
35 years after the initial operation for CNFA and 27 years after the 1st regrowth. It was managed by 212 
surgery and radiotherapy to the metastatic disease followed by temozolomide four years later due to 213 
progression. Further progress was detected three years later and three cycles of lomustine were 214 
administered, but were discontinued due to thrombocytopenia: two years later, the metastatic burden has 215 
remained unchanged. 216 
Further regrowth(s) 217 
Of the 90 patients presenting with a 2nd episode of CNFA enlargement, two were not included in the 218 
review of further outcomes (one with the pituitary carcinoma with positive staining for gonadotrophins 219 
and another patient with no follow-up scan who died shortly after the detection of CNFA progression). 220 
The remaining 88 were managed by surgery alone (n=31), radiotherapy alone (n=8), surgery combined 221 
with radiotherapy (n=11), or simply monitoring (n=38). Seven subjects had no follow-up imaging after 222 
the management of the 2nd regrowth and were excluded from the subsequent evaluations. 223 
During a median follow-up of 4.3 years (range 0.2-29.3), 22 had a 3rd regrowth (median age 66.3 years, 224 
range 44.5-73.3 - males/females 10/12). The 3rd regrowth rate at 5 years was 26.4% (Table 2, Figure 2A). 225 
When analyzed based on the modality of treatment offered for the 2nd regrowth, this was 24.4% after 226 
surgery, 0.0% after radiotherapy, 0.0% after surgery combined with radiotherapy and 48.3% after 227 
monitoring (Figure 2B).  228 
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One of these patients, who initially harbored a silent corticotroph adenoma, presented with metastatic 229 
disease in the spine 20 years after the primary surgery, and 18 years after the detection of the 1st regrowth; 230 
she died one year later. During this interval, she had developed three episodes of regrowths and clinically 231 
manifest Cushing’s disease requiring three surgical operations, two courses of radiotherapy, and gamma 232 
knife therapy.  233 
Of the 22 patients with a 3rd regrowth, 14 had further follow-up and had been managed by surgery (n=4), 234 
or monitoring (n=10); at a median period of 2.1 years (range 0.8-13.8), seven had a further adenoma 235 
enlargement (all managed by monitoring). 236 
In the whole group of patients with a 1st regrowth (and after excluding seven with no follow-up after the 237 
2nd one), the 3rd regrowth rate was 4.4% at 5 years,10.0% at 10 years and 15.1% at 15 years. On univariate 238 
Cox regression analysis, the only risk factor for this was the type of management of the 1st regrowth (type 239 
of treatment with reference category “Monitoring”: HR surgery 0.046, 95% CI 0.005-0.429, p=0.007; HR 240 
radiotherapy 0.058, 95% CI 0.011-0.313, p=0.001; HR surgery and radiotherapy 0.062, 95% CI 0.012-241 
0.309, p=0.001), whereas sex (HR 1.371, 95% CI 0.590-3.186, p=0.454), age at primary surgery (HR 242 
1.021, 95% CI 0.987-1.056, p=0.225), and immunostaining (HR 1.117, 95% CI 0.676-1.844, p=0.667) 243 
were not. 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
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Discussion  253 
This is the first large series of non-selected consecutive patients with regrown CNFA assessing 254 
systematically further tumor progression and management outcomes during a long follow-up period. We 255 
have found 5- and 10-year 2nd regrowth rates of 35.3% and 46.7%, respectively, indicating the 256 
requirement for regular, long-term monitoring. Therapeutic intervention with surgery and/or radiotherapy 257 
provided optimal outcomes, whereas with monitoring alone, there is substantial probability for further 258 
enlargement (63.4% and 81.9% at 5 and 10 years, respectively). Management approach of the regrowth 259 
(active treatment or monitoring) is the major factor determining the risk of further growth(s). The 260 
probability of multiple episodes of CNFA progression is 4.4% and 10.0% at 5 and 10 years, respectively, 261 
with the rate increasing on prolonged follow-up. Of the CNFAs with regrowth after primary treatment, 262 
0.84% had malignant transformation. 263 
Non-functioning pituitary macroadenomas comprise the most common pituitary tumor requiring surgical 264 
intervention.  However, a number of patients will experience tumor regrowth after primary treatment; 265 
thus, previously published literature analyzing the outcomes of patients from Oxford and Birmingham, as 266 
well as data from other large centers, have shown that 1st adenoma regrowth relates to the extent of CNFA 267 
removal (10-year regrowth rate if no residual adenoma 0-6% and significantly increased to 42-53% if 268 
intrasellar remnant, and to 77-80% if extrasellar remnant) (8,9,12) and to the administration of adjuvant 269 
radiotherapy, which significantly reduces adenoma progression (5-year regrowth rate 2-28%) (6,7,10,11). 270 
Furthermore, based on an Oxford cohort, the risk of enlargement increases with the length of follow-up, 271 
with 20% of the events detected at least 10 years after surgery (9). Tumor behavior after the detection of 272 
the 1st CNFA regrowth has not been previously systematically determined; the relative rarity and the 273 
generally considered slow growth rate of CNFAs possibly explain the lack of relevant data, in addition to 274 
the necessity for prolonged follow-up. In this retrospective cohort study of 237 patients with regrown 275 
CNFAs and a median follow-up of 5.9 years after the detection of the 1st regrowth, we have confirmed 276 
that tumor progression remains a significant possibility with a 10-year 2nd regrowth rate of 46.7% and 3nd 277 
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regrowth rate of 33.1%, dictating regular, life-long monitoring. Chang et al. (13) in a series of 81 regrown 278 
CNFAs (median follow-up 3.62 years), managed by surgery with or without radiotherapy, analyzed the 279 
outcome of 52 patients with follow-up more than 2 years and reported a 5-year progression rate of 8.5%. 280 
However, the small sample size and the short observation period are major drawbacks of this study.  281 
Although there is no consensus on the definition of aggressive CNFAs, it is generally considered that this 282 
group is characterized by a high risk of regrowth(s) and resistance to treatments. In our study, we have 283 
estimated the probability of multiple episodes of progression in CNFAs diagnosed with a 1st regrowth 284 
suggesting clinically aggressive behavior: this was 4.4% and 10.0% at 5 and 10 years, respectively, with 285 
the percentage increasing with further follow-up confirming the long natural history of these tumors. 286 
The decision to intervene and the modality of treatment after detection of adenoma progression depends 287 
on many factors including proximity to the chiasm/visual deterioration, tumor location/size, age, pituitary 288 
reserve, co-morbidities, available surgical and radiotherapy expertise. In 40.3% of our cases with a 2nd 289 
regrowth, imaging surveillance was the management approach; repeat surgery was offered in 14%, 290 
radiotherapy in 24.6% and surgery combined with radiotherapy in 21.2%. We found that radiotherapy 291 
(alone or in combination with surgery) offers optimal local control with 5- and 10-year regrowth rates 292 
12.5-12.7% and 17.7-26.1%, respectively. With surgery alone, these were 36.2% and 47.8%, respectively, 293 
rendering irradiation an attractive option. It should be noted, however, that the advances in imaging and 294 
surgical techniques have reduced the challenges and risks related with re-operation (14), making this 295 
approach an alternative option that could provide a stop/gap during the period when the patient wishes to 296 
avoid radiotherapy. Invasion of the cavernous sinus is not a reason for favoring surgery, but repeat 297 
operation may be inevitable for very large or close to the optic pathways tumors requiring close 298 
monitoring and early detection of continuing growth potential. Similar findings were reached after 299 
analysis of the outcomes of the 2nd regrowths, although the small sample size in each management group 300 
remains a challenge. Studies specifically looking at the impact of radiotherapy on regrown CNFAs are 301 
lacking. The published literature includes series of patients with residual or regrown adenoma managed 302 
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by various radiation modalities in tertiary radiotherapy centers which have been analyzed all together, 303 
making the estimation of clear outcomes for our group of interest not possible; nonetheless, overall 304 
optimal control rates are reported (11,15-18). In view of the suggested adverse effects of radiotherapy 305 
(19), there is controversy on its indications and timing, and in many centers, this is deferred until 306 
detection of adenoma regrowth. Within the constraints of comparing with historical data from previous 307 
literature in which radiotherapy was offered immediately after surgery (6,7,10), our outcomes after 308 
irradiation for regrowth suggest that this approach achieves similar local control rates, allowing for 309 
deferral of its use until detection of regrowth, and reducing the number of patients offered unnecessarily 310 
irradiation. This approach requires close imaging monitoring aiming to detect the regrown mass at an 311 
early stage, before its size dictates debulking surgery, and poses difficulties for the safe and effective 312 
administration of the radiotherapy. 313 
Radiographic evidence of CNFA progression does not necessarily require therapeutic intervention and 314 
imaging surveillance is a rational approach in asymptomatic regrowths or when intervention is 315 
contraindicated. The outcome of monitoring for regrown CNFAs has not been previously assessed. We 316 
found that after detection of the 1st episode of enlargement, the 5-year rate of further enlargement was 317 
63.4% (48.3% after the detection of 2nd regrowth) pointing out the importance of close monitoring and of 318 
a timely decision to intervene when the tumor is in proximity with the chiasm or shows continued 319 
progress. Amongst our regrown CNFAs managed by monitoring after a 1st regrowth, 34.8% required 320 
intervention. Factors predicting further progression have not been identified, and data on the natural 321 
history of non-operated presumed CNFAs would not apply to this specific group of tumors which have 322 
already demonstrated progressive behavior despite treatment. Notably, the growth of CNFAs is 323 
characterized by different models of unknown pathophysiology (exponential, logistic with initial growth 324 
followed by deceleration) (20), and predictive parameters are not available. Honegger et al. (20) in a 325 
selected retrospective series of 12 operated (and non-irradiated) CNFAs presenting with enlargement, 326 
found considerable variability in tumor volume doubling-time (between 1 and 27.2 years), confirming the 327 
15 
 
significant variation in tumor progression; interestingly, no significant correlation between initial volume 328 
and doubling time was confirmed. 329 
The pathophysiological mechanisms implicated in aggressive CNFA behavior have not been elucidated 330 
and validated prognostic biomarkers are not available (21). Established clinical predictors of CNFA 331 
regrowth after primary treatment are the extent of adenoma resection and post-operative irradiation 332 
(9,22,23), whereas age, sex, initial tumor size, invasiveness and histology have not been consistently 333 
verified to be of prognostic significance (24). In our series of CNFAs with already one episode of 334 
progression, type of management of the regrowth was a predictor of further progress and sex was a 335 
predictor only for the 2nd episode; the significance of the latter finding remains to be elucidated. Young 336 
age at diagnosis of the primary CNFA and type of immunostaining did not predict aggressive behavior. 337 
Notably, there is controversy as to whether CNFAs staining for ACTH demonstrate worse prognosis with 338 
multiple regrowths (25,26) and our study with 28 cases (16% of the cohort) did not support this. Notably, 339 
previous analysis of patients with CNFA in Oxford had shown that staining for ACTH was not an 340 
independent predictor of 1st regrowth (9). Nonetheless, cases of silent ACTH adenomas showing 341 
aggressive behavior after the 1st regrowth have been reported (25) and one of the two CNFAs in our study 342 
showing malignant transformation was a silent corticotroph adenoma.    343 
Pituitary carcinomas account for 0.1% of pituitary tumors and require multidisciplinary treatment 344 
approach (27). Data on the rate of regrown CNFAs demonstrating malignant transformation have not 345 
been previously published. In our series, malignant transformation was diagnosed in 0.8% of CNFAs 346 
diagnosed with regrowth. Although latency periods between 4 months to 18 years have been reported, in 347 
our cases the interval was extensive (21 and 35 years). Overall, prognosis is poor and most of the patients 348 
die within one year of diagnosis (27). However, one of our patients had an unusual clinical course with 349 
survival of at least 9 years, highlighting the unpredictable behavior of this condition. The development of 350 
florid Cushing’s syndrome and malignant transformation from a silent corticotroph adenoma, as in our 351 
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second case of pituitary carcinoma, is exceptionally rare and the biological mechanisms remain 352 
enigmatic. 353 
The limitations of our study are its retrospective, non-randomized nature making it vulnerable to selection 354 
bias for the management approaches (however, a prospective randomized study may not be practically 355 
feasible) and the fact that a (small) number of patients lacked follow-up after detection of further 356 
enlargement (in most of them repeat imaging had not taken place by the end of the project). The 357 
advantages are the large number of well characterized and non-selected subjects with a rare condition 358 
from two large pituitary UK referral centers followed-up for a long period, who were analyzed 359 
systematically in terms of tumor progression, providing novel data for clinical practice. 360 
Our study provides novel and systematic data on the previously unknown natural history of regrown 361 
CNFAs and on the poorly explored area of clinically aggressive CNFA behavior. It establishes the 362 
importance of continuing follow-up after therapeutic interventions, as these do not offer definitive tumor 363 
stability. It also proves the significance of regular, long-term monitoring of regrown CNFAs not offered 364 
treatment, as continued progress is seen in a substantial number of patients who will ultimately require 365 
intervention. The decision for intervention needs to be taken in a multidisciplinary setting and will rely on 366 
a risk-benefit balance with one of the major factors being the prevention of visual morbidity. Given that a 367 
prospective study of this scale and duration is unlikely to be feasible, our results aid decision making for 368 
all disciplines involved in the management of these patients (endocrinology, oncology, neurosurgery) and 369 
highlight the necessity of gaining a better understanding of the biological behavior of these tumors.  370 
 371 
 372 
 373 
 374 
 375 
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Figure 1. Kaplan-Meier 2nd regrowth-free survival curves (A) total group of patients with a 1st 497 
regrowth, (B) stratified by type of treatment of the 1st regrowth (surgery, radiotherapy, surgery and 498 
radiotherapy, monitoring). 499 
 500 
 501 
Figure 2. Kaplan-Meier 3rd regrowth-free survival curves (A) total group of patients with a 2nd 502 
regrowth, (B) stratified by type of treatment of the 2nd regrowth (surgery, radiotherapy, surgery 503 
and radiotherapy, monitoring). 504 
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Table 1. Characteristics of patients with regrown CNFA 532 
 533 
Number of patients 
 
237  
Sex n (%) (males/females) 
 
134/103 (56.5%/43.5%) 
Age at time of surgery for primary CNFA (years) (median, range) 
 
52.1 (12-86) 
Immunostaining of adenoma* n (%) 
   FSH/LH or their subunits 
   Null cell 
   ACTH1 
   Plurihormonal2 
   GH 
   PRL 
 
67 (40.4%) 
60 (36.1%) 
28 (16.9%) 
9 (5.4%) 
1 (0.6%) 
1 (0.6%)  
 
Adjuvant radiotherapy after surgery of primary CNFA n (%) 
 
30 (12.7%) 
Interval of diagnosis of 1st regrowth from date of surgery of primary 
CNFA (months) (median, range) 
 
50 (3-485) 
Management of 1st regrowth3 n (%) 
Surgery  
Radiotherapy 
Surgery and adjuvant radiotherapy4 
Monitoring 
 
33/236 (14.0%) 
58/236 (24.6%) 
50/236 (21.2%) 
95/236 (40.3%) 
Primary CNFA: CNFA at the time of original diagnosis (before any regrowth). 534 
Radiotherapy: fractionated external irradiation in all cases except two in which radiosurgery was offered. 535 
*Data are provided based on 166 cases with the relevant information available. 536 
1Combined or not with other hormones. 2Combination of hormones other than ACTH. 3One patient, who died 537 
shortly after the diagnosis of regrowth and had no follow-up scan, has been excluded. 4Two patients from this group 538 
had also received radiotherapy as adjuvant treatment after the original surgery of the primary CNFA.  539 
 540 
 541 
 542 
 543 
 544 
 545 
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Table 2. 2nd and 3rdregrowth rates at 5 and at 10 years follow-up 546 
 547 
Group of patients  2nd regrowth rate at 5 years  2nd regrowth rate at 10 years 
Total group* 35.3% 
Males 28.2% 
Females 44.7% 
46.7% 
Males 38.8% 
Females 57.0 % 
Surgery for 1st regrowth 36.2% 47.8% 
Radiotherapy for 1st regrowth 12.5% 17.7% 
Surgery and Radiotherapy for 1st regrowth 12.7% 26.1% 
Monitoring for 1st regrowth 63.4% 81.9% 
Group of patients  3rd regrowth rate at 5 years  3rd regrowth rate at 10 years 
Total group 26.4% 33.1% 
Surgery for 2nd regrowth 24.4% 35.2% 
Radiotherapy for 2nd regrowth 0.0% 0.0% 
Surgery and Radiotherapy for 2nd regrowth 0.0% 0.0% 
Monitoring for 2nd regrowth 48.3% 58.6% 
* 2nd regrowth rate for the total group within the follow-up period: 38%. 548 
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